SynthesisJournal of ovarian research2025
The association between serum antinuclear antibodies and premature ovarian insufficiency: a meta-analysis.
Synthesis in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAutoimmune dysfunction is a recognized contributor to primary ovarian insufficiency (POI), and antinuclear antibodies (ANA) are widely used to assess autoimmune activity. Although many studies have examined the association between ANA and POI, their findings remain inconsistent. This meta-analysis aims to clarify the correlation between ANA positivity and POI and to evaluate the potential of ANA as a serological marker of autoimmune involvement in POI.
methodsWe systematically searched PubMed, EMBASE, Cochrane Library, CNKI, VIP, and WanFang Data for case-control studies published up to August 2024. Manual reference screening was also performed. Studies comparing antinuclear antibody (ANA) positivity between women with primary ovarian insufficiency (POI) and controls were included. A random-effects model was used to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity and publication bias were assessed using the I² statistic and Begg's test.
resultsAccording to the analysis of all 13 studies, ANA positivity was significantly associated with POI (OR 2.57, 95% CI: 1.62-4.08, Z = 4.001, P < 0.001). No significant heterogeneity was observed in the primary outcome (I
conclusionANA positivity is significantly associated with an increased risk of POI, supporting its potential role as a serological marker for early screening. Routine ANA testing may be particularly valuable in women under 35 years of age or with FSH > 40 IU/L. Future large-scale studies should focus on optimizing ANA detection methods (e.g., enzyme-linked immunosorbent assay [ELISA] vs. IIF), quantifying titers, and evaluating nuclear patterns to improve diagnostic accuracy and clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.